CLINICAL TRIALS AND OBSERVATIONS Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
نویسندگان
چکیده
1Leukemia Department, University of Texas M. D. Anderson Cancer Center, Houston, TX; 2Cancer Therapy & Research Center, University of Texas Health Science Center, San Antonio, TX; 3Stanford University Cancer Center, Stanford, CA; 4University of California at Los Angeles, Los Angeles, CA; 5Division of Hematological Oncology, Roswell Park Cancer Institute, Buffalo, NY; 6Mount Sinai School of Medicine, New York, NY; and 7Amgen Inc, Thousand Oaks, CA
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
This multicenter phase 2 study evaluated the use of tipifarnib (R115777) in patients with poor-risk myelodysplastic syndrome (MDS; French-American-British classification). Patients (n 82) received tipifarnib 300 mg orally twice daily for the first 21 days of each 28-day cycle. Twenty-six patients (32%) responded to tipifarnib: 12 (15%) complete responses (CRs) and 14 (17%) hematologic improveme...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
Ruxolitinib is JAK1/JAK2 inhibitor with established clinical benefit in myelofibrosis (MF). We analyzed long-term outcomes of 107 patients with intermediate-2 or high-risk MF receiving ruxolitinib at MD Anderson Cancer Center (MDACC) on phase 1/2 trial. After a median of 32 months of follow-up, 58 patients (54%) were still receiving ruxolitinib, with overall survival (OS) of 69%. The splenomega...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
The combination of a DNA hypomethylating agent with a histone deacetylase inhibitor has synergistic antileukemia activity and may restore sensitivity to all-trans retinoic acid (ATRA). We conducted a phase 1/2 study of the combination of 5-azacitidine (5-AZA), valproic acid (VPA), and ATRA in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. 5-AZA was administered subc...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome
The erythropoietic effects of lenalidomide are cytokine dependent, suggesting that the erythroid hematologic improvement (HI-E) rate may be augmented by combined treatment (CT) with recombinant human erythropoietin (rhu-EPO) in myelodysplastic syndrome (MDS). In the present study, we explored the benefits of CT and the relationship between lenalidomide pharmacokinetics and hematologic toxicity ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q
1Rush University Medical Center, Chicago, IL; 2Florida Cancer Specialists, Fort Myers; 3Weill Medical College of Cornell University, New York, NY; 4Mayo Clinic, Rochester, MN; 5James P. Wilmot Cancer Center, University of Rochester Medical Center, NY; 6Fred Hutchinson Cancer Research Center, Seattle, WA; 7Eisenhower Medical Center, Rancho Mirage, CA; 8Karmanos Cancer Institute, Wayne State Univ...
متن کامل